Protara Therapeutics, Inc. TARA R2K
Healthcare · Biotechnology · United States
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
READ MORE ›$4.65
+52.96% 1Y
Market & Price
Market Cap
$261.35M
Current Price
$4.65
High / Low (52W)
$7.56 / $2.78
Beta
1.52
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$3.67
Price to Book
1.27
P/S
-
EV/EBITDA
-1.85
Dividend Yield
-
Profitability & Returns
ROCE
-32.51%
ROE
-37.27%
ROA
-24.29%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.31
EPS (TTM)
$-1.36
Balance Sheet & Liquidity
Debt/Equity
1.69
Quick Ratio
15.39
Current Ratio
15.69
Debt
$3.06M
Total Assets
$209.47M
Current Assets
$159.50M
Working Capital
$148.56M
Ownership
Promoter Holding
2.39%
Chg in Prom Hold
-
FII / Inst Holding
82.36%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$128.62M
Total Revenue (TTM)
-
EBITDA
$-69.69M
Free Cash Flow
$-39.34M
Operating Cash Flow
$-62.99M
Shares Outstanding
56.20M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
4.30%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Trading 38.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TARA Protara Therapeutics, Inc. R2K | 4.65 | - | $261.35M | - | -32.51% | -37.27% | - | 4.30% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 2.95M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.12M | 16.59M | 14.76M | 19.08M | 19.63M |
| Operating Income | - | -1.93M | -2.51M | 134.00K | - | -4.62M | -4.98M | -5.08M | -6.82M | -7.85M | -7.17M | -6.48M | -5.99M | -12.31M | -6.37M | -5.00M | -4.62M | -1.53M | -1.43M | -2.35M | -10.16M | -7.27M | -8.06M | -13.58M | -12.79M | -10.83M | -10.87M | -8.71M | -7.97M | -9.73M | -12.14M | -10.70M | -11.85M | -10.66M | -12.33M | -14.12M | -16.59M | -14.76M | -19.08M | -19.63M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.04M | -16.49M | -14.67M | -18.99M | -19.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.91M | -14.96M | -13.26M | -17.31M | -17.78M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.40M | -2.83M | -2.56M | -5.18M | 7.23M | -4.58M | -5.07M | -5.38M | -6.55M | -7.91M | -7.11M | -6.50M | -5.61M | -12.31M | -6.08M | -4.88M | -4.51M | -1.53M | -1.43M | -2.35M | -10.06M | -7.14M | -7.97M | -13.46M | -12.78M | -10.78M | -10.76M | -8.54M | -7.69M | -9.04M | -11.29M | -9.86M | -11.10M | -9.51M | -11.22M | -11.91M | -14.96M | -13.26M | -17.31M | -17.78M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.14 | -0.96 | -0.96 | -0.76 | -0.68 | -0.80 | -1.00 | -0.87 | -0.97 | -0.45 | -0.50 | -0.29 | -0.35 | -0.31 | -0.37 | -0.31 |
| R&D Expense | - | 1.19M | 1.60M | 1.77M | - | 2.63M | 3.09M | 3.08M | 4.35M | 5.24M | 4.84M | 4.25M | 3.89M | 10.34M | 4.07M | 2.76M | 2.35M | 1.08M | 986.72K | 1.10M | 3.06M | 2.47M | 2.80M | 7.04M | 5.89M | 4.09M | 5.27M | 3.08M | 3.47M | 5.14M | 7.25M | 6.22M | 7.75M | 6.39M | 8.07M | 9.15M | 10.77M | 9.59M | - | 13.56M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 2.95M | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 37.55M | 43.61M | 49.15M | 64.55M |
| Operating Income | -8.00M | -7.12M | -7.58M | -20.87M | -28.70M | -30.36M | -21.37M | -7.83M | -34.44M | - | -37.55M | -43.61M | -49.15M | -64.55M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -64.57M | -43.27M | -48.82M | -64.19M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 1.74M | 1.14M | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -65.95M | -40.42M | -44.60M | -57.44M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -7.97M | -7.91M | -3.34M | -21.38M | -28.53M | -29.96M | -20.73M | -7.83M | -33.98M | - | -65.95M | -40.42M | -44.60M | -57.44M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -4.21 | -5.86 | -3.57 | -2.17 | - |
| R&D Expense | 5.91M | 3.99M | 6.43M | 12.38M | 18.87M | 21.69M | 11.85M | 3.88M | 11.98M | 21.09M | 16.81M | 24.99M | 31.70M | 42.63M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 4.30% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +52.96% |
| 6 Months: | -38.49% |
| 3 Months: | -26.89% |
| 1 Month: | -10.06% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.66M | 84.80M | 67.54M | 43.52M | 43.98M | 23.52M | 1.22M | 203.16M | - | 113.29M | 78.95M | 181.45M | 209.47M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 86.15M | 68.70M | 172.16M | 159.50M |
| Cash & Equivalents | 3.27M | 2.41M | 2.79M | 68.84M | 40.03M | 36.39M | 21.17M | 19.37M | 564.00K | 168.60M | - | 24.13M | 39.59M | 162.80M | 49.66M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 486.00K | 242.00K | 0 | 1.26M |
| Total Liabilities | - | - | 9.77M | 2.34M | 4.13M | 5.08M | 9.24M | 3.08M | 3.35M | 3.91M | - | 11.21M | 10.63M | 14.32M | 13.06M |
| Current Liabilities | - | - | 9.77M | 2.34M | 4.13M | 5.08M | 9.24M | 3.08M | 3.35M | 2.92M | - | 5.74M | 6.15M | 10.96M | 10.94M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 6.38M | 5.47M | 4.48M | 3.36M |
| Total Equity | -72.66M | -86.66M | -100.51M | 82.46M | 63.41M | 38.44M | 34.74M | 4.78M | -2.13M | 199.24M | - | 102.08M | 68.32M | 167.13M | 196.41M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 11.27M | 11.36M | 35.04M | 53.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -17.57M | -23.69M | -22.35M | -23.23M | -5.01M | -23.41M | - | -26.46M | -37.56M | -35.81M | -56.37M |
| Investing Cash Flow | - | - | - | -11.33M | 19.92M | -16.10M | 18.43M | -475.00K | 2.83M | - | 14.95M | 53.11M | 19.16M | -139.49M |
| Financing Cash Flow | - | - | - | 163.00K | 208.00K | 23.05M | 2.98M | 500.00K | 189.40M | - | -90.00K | -91.00K | 139.87M | 82.72M |
| Capital Expenditure | -67.00K | -10.00K | -51.00K | -198.00K | -271.00K | -35.00K | -119.00K | -475.00K | -884.00K | - | -120.00K | -45.00K | -63.00K | -94.00K |
| Free Cash Flow | - | - | - | -17.76M | -23.96M | -22.39M | -23.35M | -5.49M | -24.29M | - | -26.58M | -37.60M | -35.87M | -56.46M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -11.60M | 15.46M | 123.21M | -113.14M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | 228.00K | 90.00K | 91.00K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -257.1% | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | -113.4% | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 9.2% | 7.9% | -4.1% | -33.7% | -74.2% | -86.3% | -433.8% | 368.0% | -17.1% | - | -64.6% | -59.2% | -26.7% | -29.2% |
| ROCE % | - | 173.3% | -9.2% | -32.9% | -74.7% | -87.4% | -104.5% | 368.0% | -17.2% | - | -34.9% | -59.9% | -28.8% | -32.5% |
Shareholding Pattern
Insiders
2.39%
Institutions
82.36%
Public Float
84.38%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Janus Henderson Group PLC | 9.26% | 5.21M | $24.21M |
| 2 | Blackrock Inc. | 6.04% | 3.39M | $15.79M |
| 3 | Velan Capital Investment Management LP | 5.04% | 2.83M | $13.18M |
| 4 | Millennium Management Llc | 5.04% | 2.83M | $13.17M |
| 5 | Blackstone Inc | 4.03% | 2.27M | $10.53M |
| 6 | Vanguard Capital Management LLC | 3.77% | 2.12M | $9.85M |
| 7 | Sio Capital Management, LLC | 3.50% | 1.97M | $9.16M |
| 8 | Acorn Capital Advisors, LLC | 3.12% | 1.75M | $8.15M |
| 9 | Integral Health Asset Management, LLC | 3.11% | 1.75M | $8.14M |
| 10 | AIGH Capital Management LLC | 2.89% | 1.62M | $7.55M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TARA
No recent headlines available.